A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

NCT02601625 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety
Pharmacokinetics
Healthy Subjects

Interventions

DRUG: Anifrolumab SC injection (300mg)
DRUG: Anifrolumab IV infusion (300mg)
DRUG: Anifrolumab SC infusion (600mg)
DRUG: Anifrolumab placebo SC injection (300mg)
DRUG: Anifrolumab placebo IV infusion (300mg)
DRUG: Anifrolumab placebo SC infusion (600mg)

Sponsor

AstraZeneca